七甲基瓜宁在体内抑制结肠癌生长
K I Kirsanov1,2, T I Fetisov1, E E Antoshina1
1Blokhin National Medical Research Center of Oncology, Institute of Carcinogenesis, Moscow, 115478 Russian Federation.
Acta naturae
|August 27, 2024
概括
7-甲基 (7-MG) 抑制了癌细胞生长的关键酶. 这项研究表明,在临床前模型中,7-MG有效地透瘤并抑制结肠腺癌.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 7 - 甲基 (7-MG) 是一个天然的抑制物,可抑制多 (ADP-ribose) 聚合酶1和tRNA-氨酸转糖酶.
- 这些点的酶活性对癌细胞增殖至关重要.
- 临床前研究已经确定了小鼠7-MG的安全性和胃内给药方案.
研究的目的:
- 调查7-甲基瓜宁 (7-MG) 的药理活性.
- 评估7-MG在抑制瘤生长中的疗效.
- 为了评估7-MG的瘤透率.
主要方法:
- 在BALB/c和BALB/c裸体小鼠模型中进行药理活性评估.
- 移植瘤模型包括Akatol结肠腺癌和人类HCT116异种移植.
- 对7-MG瘤组织透和生长抑制的评估.
主要成果:
- 7 - 甲基瓜宁 (7-MG) 证明了有效的透到瘤组织.
- 在Akatol模型中,7-MG显著抑制结肠腺癌的生长.
- 在异种移植模型中,7-MG还抑制了人类HCT116细胞的生长.
结论:
- 7-甲基 (7-MG) 对结肠腺癌具有显著的抗瘤活性.
- 这些发现支持7-MG作为结肠癌治疗剂的潜力.
- 对7-MG的机制和临床应用的进一步研究是有必要的.
更多相关视频
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
10.0K
14:12HPLC Measurement of the DNA Oxidation Biomarker, 8-oxo-7,8-dihydro-2’-deoxyguanosine, in Cultured Cells and Animal Tissues
Published on: August 1, 2015
27.1K
相关概念视频
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
